Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock RisesZacks Investment Research • 07/30/26
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call TranscriptSeeking Alpha • 07/29/26
Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE ListingBenzinga • 07/29/26
Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 07/29/26
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 OutlookBusiness Wire • 07/29/26
Stay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key MetricsZacks Investment Research • 07/28/26
Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.The Motley Fool • 07/26/26
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supplyCNBC • 07/22/26
Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo StudyMarketBeat • 07/12/26
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple SclerosisBusiness Wire • 07/09/26
Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b TranscriptSeeking Alpha • 07/07/26
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?The Motley Fool • 07/06/26
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?The Motley Fool • 06/19/26